Prescient Therapeutics LimitedASX: PTX

Encouraging Pre-Clinical Data Presented at US Cancer Meeting

· Issued by Prescient Therapeutics Limited

Filed with ASX · · 2 pages · English

 Novel compound PTX-100 shown to decrease multiple myeloma tumours, improve median survival times  Data to be presented at American Association for Cancer Research Annual Meeting Melbourne, Australia – 21 April 2015– Prescient Therapeutics (ASX: PTX), a clinical stage oncology company, will announce today highly encouraging data from a pre-clinical trial of its novel compound PTX-100 (formerly k

Prescient Therapeutics Limited on 6ix

Earlier from Prescient Therapeutics

All Prescient Therapeutics news releases